Protein Labeling Market is Estimated to Grow Due to Increase in Incidences of Chronic Diseases

Global Protein Labeling Market is anticipated  to reach USD 2,602.0 million by 2024, according to a new report by Grand View Research, Inc.Growing adoption of bioengineering technologies and rise in spending on R&D leading to a reduction in process complexity for protein labeling is expected to drive market growth.

View Summary Of This Report Click Here: www.goo.gl/aNb5mG

Anticipatedlaunch & commercialization of novel products and ongoing improvement in techniques used for proteomic research is expected to further reinforce growth in demand. Improvements in accuracy, resolution and procedures used in techniques such as fluorescence&biorthogonaltagging are estimated to grow over the forecast period. 

Ongoing development of genetic sequencing methodologies and consequent reduction in the cost of genome profiling is likely to drive demand for the next step of genetic analysis, i.e., protein expression analysis. Growth in a number of such protein profiling studies is expected to directly fuel demand for genomic and proteomic labeling techniques through to 2024. 

Further key findings from the report suggest:

• The reagents used for protein labeling accounted for the largest share of revenue in 2015. The larger share can be accounted for by the presence of high demand for labeling of peptides, antibodies and proteins at reaction locations of functional amino acids, and development of novel reagents that have chemo selective capabilities & amino acid cross linking abilities. 
• Application of protein labeling in immunological techniques was observed to be responsible for generation of the largest share of revenue in 2015. Addition of nanoparticle-based tagging owing to ongoing R&D in emerged with the advent of nanoparticles and nanotechnology. Furthermore, aptamers-mediated nanoparticle-based peptide labeling method is gaining rapid acceptance for use in intracellular imaging and dynamic process tracking. 
• Dye-based or fluorescence-based protein labeling have been observed to demonstrate high market adoption owing to associated usage in assays like ELISA, western blotting. Ongoing increase in the number of genetics-based R&D projects are also expected to boost market demand. 
• On the basis of the experimental design, the market can be broadly categorized as in-vitro and in-vivo methodologies. A more minute analysis reveals that a further segment wise classification is also possible. Key segments from the sub-categorization are enzymatic &photo reactive tagging for the segments respectively. As enzymatic marking provides more flexibility of and has application in identification for a number of peptide profiling requirements, the segment is expected to witness lucrative growth over the forecast period.
• North America accounted for over 45%of total revenue generated for 2015 owing to the presence of a very large installed base of genetic and proteomic profiling platforms across the U.S. High market usage of peptide identification techniques to be used in sequencing and expression analysis projects in a number of academic and clinical research institutes is another key factor responsible for the region’s large share. 
• Key players operating in this industry include Thermo Fisher Scientific Inc., General Electric Healthcare Life Science, PerkinElmer Inc, Merck Millipore, Promega Corporation, LI-COR Inc., F. Hoffmann-La Roche AG, New England Biolabs, Eurogentec S.A., Kirkegaard & Perry Laboratories (KPL).

Request For Free Sample: www.goo.gl/RmMGqs

Rising Prevalence of Oncology, Neurology, and Cardiology-based Diseases is Expected to Drive the Growth of Biomarkers Market

The global Biomarkers Market is expected to reach over USD 78.2 billion by 2024, according to a new report by Grand View Research, Inc. The growing demand for companion diagnostics and the rising adoption of personalized medicine are the key factors propelling the growth of the biomarkers market. The increasing need of disease-specific biomarkers for the development of diagnostics, the increasing R&D funding, and the rising prevalence of oncology and cardiovascular-based diseases are anticipated to create significant opportunities for the market growth during the forecast period.

View Summary Of This Report Click Here: www.goo.gl/v3kboq

The spiraling population and the upward trend in the adoption of sedentary lifestyles are expected to provide the industry with a huge target population base. Government grants and research funding for the discovery and development of novel biomarkers are the other factors accentuating the market growth. The introduction of the biomarker-based diagnostic kits for screening high-risk population coupled with the growing prevalence of genetic disorders is also anticipated to increase the client base for this market.

Further key findings from the study suggest:

• The safety biomarkers segment held the largest share of over 40% in 2015 owing to the increasing routine healthcare checkups and the growing base of the geriatric population that is at a high risk of developing various diseases
• The validation biomarkers segment is determined as one of the fastest growing segments. The increasing R&D initiatives for the development of more specific biomarkers, and hence the subsequent development of companion diagnostics with enhanced accuracy and sensitivity for the effective detection of diseases are key factors contributing towards the aforementioned growth.
• The drug discovery segment dominated the application segment in 2015. Biomarkers are extensively used by pharmaceutical companies to accelerate the development of new drug findings and to predict the failure of the upcoming drugs.
• The diagnostic segment is estimated to witness a lucrative growth over the forecast period owing to the growing awareness about routine healthcare checkups and the rising prevalence of various diseases
• In 2015, the oncology segment dominated with a revenue generated over USD 9.2 billion owing to the introduction of companion diagnostic tests for oncology drugs and the growing burden of cancer across the globe
• The cardiovascular segment is expected to be the fastest growing segment with a CAGR of over 14.0%. The growing adoption of sedentary lifestyles and the rise in the obese population base leading to cardiovascular diseases are estimated to provide this market with a potential growth platform.
• North America held the largest regional share of around 39% in 2015. The well-established R&D infrastructure and the high level of disposable income are the factors contributing towards the large market share.
• Asia Pacific is anticipated to be the fastest growing biomarker market owing to the factors, such as the developing economic conditions, a large base of the target population, and a favorable regulatory scenario for clinical trials.
• Major players include Roche Diagnostics Ltd., Abbott Laboratories, Inc., Agilent Technologies, Inc., Epigenomics AG, GE Healthcare, Johnson and Johnson, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Siemens Healthcare GmbH, Qiagen, Inc., Merck& Co., Inc., and others
• Market participants are ensuring stability by fundingthe growing R&D initiatives and focusing on the developing countries through the expansion and introduction of novel biomarker diagnostics.In 2015, Pfizer, Inc. developed a lung cancer therapy drug, Crizotinib used in non-small cell lung cancer therapy associated with ALK fusions.

Request For Free Sample: www.goo.gl/eq4LjA

Awareness of Vaccination Benefits through Immunization Boosting the Vaccine market Growth

The global Vaccine Market is expected to reach over USD 77.5 billion by 2024, according to a new report by Grand View Research, Inc. The presence of numerous molecules in the pipeline is anticipated to meet the demand for efficient vaccines. These include vaccines for chest infection, tuberculosis, malaria, and dengue. Most of the key players are actively leveraging on their vaccine development technologies to launch novel preventative solutions with an objective to increase their market share. For instance, Pfizer, Inc. is involved in the development of vaccines to prevent severe infections caused by Meningococcal B, Clostridium difficile, and Staphylococcus aureus.

Furthermore, the broad coalition of governments, worldwide, working to promote the awareness of vaccination benefits through immunization programs with the objective of containing the propagation of communicable diseases that are associated with high morbidity and mortality is expected to stimulate the market growth.

View Summary Of This Report Click Here: www.goo.gl/3DNG17

For instance, the ‘Immunize Australia Program’ sponsors the immunization of individuals, which acts as a preventative action in preventing disease occurrence and checks rampant disease transmission thus protecting millions of Australians from severe diseases. Another program that has been involved in achieving extensive immunization coverage on the Indian continent is the National Immunization Program, a government program that has focused on taking strong preventive measures to offset vaccine-preventable diseases, particularly in children.  

Further key findings from the study suggest:

• The inactivated vaccine type segment was estimated to have over 14.5% market share in 2015 owing to the related advantages including easy storage and transport due to the highly stable nature of these vaccines. In December 2015, Sanofi Pasteur, Inc. launched a new trivalent, inactivated polio vaccine in India.
• The DNA vaccine segment is presumed to be the fastest growing type over the forecast period owing to the ease of production compared to the cell-based vaccines and the promising, targeted immunization outcomes coupled with the continual developments in the biotechnology area. Other advantages associated are ease of production, long lasting immunogenicity, and no risk of reversion.
• The cancer application segment is expected to witness the fastest growth with a CAGR of over 11.8% in the vaccinations market majorly attributable to the need for immunization against cancer coupled with the increasing prevalence of various types of cancer, such as cervical and colorectal cancers.
• North America dominated the market in terms of revenue with over USD 12 billion in 2015, due mainly to the presence of extensive research and development activities and the existence of key participants of the industry in this region
• Asia Pacific is identified to witness a lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India. Moreover, the availability of skilled labors at a lower cost and the low manufacturing operations cost provide a platform for clinical trial outsourcing of the vaccinations under development to expedite commercialization.
• Leading players in this industry, among others are, Merck & Co., Inc., Emergent BioSolutions, Inc., Johnson and Johnson, Sanofi Pasteur, Inc., Pfizer, Inc., Novartis AG, CSL Ltd., and GlaxoSmithKline Plc. Other prominent players include Abbott Laboratories, Inc., AstraZeneca plc, Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals Company Ltd., and Valeant Pharmaceuticals International, Inc.
• In April 2016, VBI vaccines, Inc. entered into a collaborative agreement with Sanofi Pasteur, Inc. to employ its “Lipid Particle Vaccine” formulation technology to better the stability of the Sanofi vaccines.

Request for free sample: www.goo.gl/zeD5cn

Automations in Clinical Laboratories is a Key Factor Affecting Cell Surface Marker Detection Market

The global Cell Surface Marker Detection Market is expected to reach USD 6.49 billion by 2022, according to a new report by Grand View Research, Inc. This growth in demand can be attributed to rise in incidence of oncology diseases and other cell-associated disorders. 

Rapid introduction of advancements and automations in clinical laboratories is a key factor affecting this industry. Incorporation of novel algorithms pertaining to diagnosis and prognosis of chronic disorders is expected to fuel demand of this market in the coming years.

View Summary Of This Report Click Here: www.goo.gl/f8RcCD

Requirement of solutions for data handling and interpretation of clinical conditions based on obtained results are anticipated to enhance potential for R&D in this sector, consequently driving market growth over the forecast period. 

Further key findings from the report suggest:

• Flow cytometry devices accounted for over 70% of the revenue generated in the industry for 2014. This large share can be attributed to the growing advancement in these instruments such as enhancement in efficiency and resolution of fluorescence-based cytometric detectors. Furthermore, presence of large product portfolio of different industry players operating in cytometry is responsible for large market share of this technique. 
• Disease diagnosis and identification accounted for over 50% of the revenue generated in the market for 2014. High incidence rate of cell-associated disorders and oncology diseases that need to be treated in order to curb the mortality rate are the major drivers for growth of this segment. 
• Determination of novel drug targets and development of biopharmaceuticals for prognosis of chronic diseases is anticipated to propel growth of research and drug discovery sub-segment in the coming years. With expected development of this segment, the sector will witness lucrative growth over the forecast period. 
• North America accounted for the largest share of this sector for 2014, as there are is significantly high number of research and development projects ongoing in the region related to cytological investigation for proteomics, genomics, and drug and vaccine development. Growing need for biopharmaceuticals is also anticipated to fuel regional growth. 
• North America dominated the industry in 2014, with revenue estimated at USD 999.0 million. Presence of sophisticated healthcare infrastructure and favorable government initiatives with respect to analytical techniques and their applications for disease diagnosis and drug development are some key factors likely to drive growth. 
• Asia Pacific is expected to witness lucrative growth from 2015 to 2022 due to the presence of high-unmet medical needs coupled with rapidly rising healthcare R&D investment and growing medical expenditures in emerging economies of India and China 
• Key participants of the cell surface marker detection industry include Siemens Healthcare, Nihon Kohden Corporation, Sartorius, Janssen Diagnostics Inc., Grifols SA, Thermo Fisher Scientific, BioRad Laboratories Inc., and F. Hoffman La Roche Ltd. 
• These participants are involved in R&D for production of cell-specific antibodies and collaborations with smaller entities operating in the market as well as with academic research laboratories in order to maintain their market position and enter the untapped market regions 

Request for free sample of "Cell Surface Marker Detection"Analysis Report: www.goo.gl/bZjm9s

Gene Expression Market Worth $11.3 Billion By 2025

The global Gene Expression Market is expected to reach USD 11.3 billion by 2025, according to a new report by Grand View Research, Inc. Globally rising demand for targeted molecular therapeutics coupled with rising adoption of precision medicine is anticipated to fuel market growth.

Understanding gene expression under different conditions as well as the effects it has on different metabolic activities has opened various vistas for the development of a novel generation of molecular therapeutics. Search for methods to manipulate the way a coding DNA is expressed as a cure to different conditions arising due to abnormally expressed genes is expected to drive market.

View Summary Of This Report Click Here: www.grandviewresearch.com/industry-analysis/gene-expression-analysis-market

Drug discovery and development was estimated with largest share owing to higher adoption in drug response testing for severs and complicated diseases such as all types of cancer, tuberculosis, cardiac conditions and rare genetic disorders. However, clinical diagnostic application is projected with fastest growth owing to rising demand for rapid and accurate diagnosis of complex diseases coupled with their higher incidence.

Rising demand for precision medicine, higher prevalence of genetic disorders, and rapid advances in biotechnology is attributive to largest contribution to revenue by North America. Owing to the presence of countries, witnessing rapid economic developments and demand for better health care solutions Asia Pacific is anticipated to witness the fastest growth.

Further key findings from the report suggest:

• RNA expression dominated the market with respect to analysis technique as the increased interest of researchers has been observed to have been directed to understanding RNA activity to better understand its effects on diseases
• As there are a high number of products available for low to mid-plexing of gene expression, the segment was observed to have accounted for the higher share
• Rising focus on higher accuracy is anticipated to drive growth of high-plex techniques.
• Moreover, increased focus on cancer genomic is anticipated to bolster growth
• Introduction of improved data analytics & interpretation with high turnaround efficiency coupled with increase in incidences of target diseases are vital factor influencing R&D.
• Substantial adoption of gene expression techniques the U.S. can be attributed for the largest share of North American market.
• Asia Pacific is anticipated to witness a high growth rate due to the presence of initiatives by key market participants to enhance presence in these emerging economies due to the presence of untapped potential
• Key players contributing in this market are Qiagen, Quest Diagnostics Incorporated, Illumina, Bio-Rad Laboratories, Oxford Gene Technology, TAKARA,Biocartis Group NV, MYRIAD GENETICS, INC.

To learn more about this report: www.goo.gl/ePF5k5

Stem Cells Market Gained Significant Attention from Multidisciplinary Community of Scientists

The global Stem Cell Market is expected to reach USD 15.63billion by 2025, growing at a CAGR of 9.2%, according to a new report by Grand View Research, Inc. Augmentation in research studies that aim at broadening the utility scope of associated products is anticipated to drive the market growth. These research projects have opened the possibility of implementation of several clinical applications of these cells, thereby impacting disease-modifying treatments.

View Summary Of This Report Click Here: www.grandviewresearch.com/industry-analysis/stem-cells-market

Scientists are engaged in discovering novel methods to create human stem cells. This is to address the increasing demand for stem cell production for potential investigation in disease management. This factor is certainly expected to accelerate the development of regenerative medicine, thus driving industrial growth.

Moreover, cellular therapies are recognized as the next major advancements in transforming healthcare. Firms are expanding their cellular therapy portfolio, understanding the future potential of this arena in the treatment of Parkinson's disease, type 1 diabetes, spinal cord injury, Alzheimer's disease, and others.

In March 2016, Scientists at Michigan State University unveiled new kind of cells “induced XEN cells” from a cellular trash pile. This discovery is expected to drive advancements in regenerative medicine. Such discoveries are anticipated to bolster research and sales in this market over the forecast period.

Further key findings from the report suggest:

• Adult stem cells dominated the market and is expected to maintain its dominance. This can be attributed to the several factors such as lower rejection rates, long term renewal property, and no ethical concerns associated with their usage
• Application wise regenerative medicine is estimated to hold the substantial share of the revenue
• Presence of significant number pipeline projects for regenerative medicine is expected to fuel growth in the market
• In addition, exploding research projects have driven the need of harvesting techniques, thereby propelling progress of acquisition technology
• Increased R&D activities and huge funds granted by funding bodies to advance cellular research in the U.S. have resulted into the large share of North America
• Extensive research carried out in Singapore and Japan is anticipated to drive progress with lucrative avenues
• Advanced Cell Technology Inc, Osiris Therapeutics Inc, Celgene Corporation, BIOTIME, INC., Cynata, and STEMCELL Technologies Inc., are some of the major companies operating in this market
• A number of companies are engaged in seeking investment from overseas organizations and also developing partnerships with the pharmaceutical organizations

To learn more about this report: www.goo.gl/HD4K5u

Protein Detection & Quantification Market Offers Opportunities for Stratification, Diagnosis, and Disease Monitoring

The global protein detection & quantification market is expected to reach USD 3.00 billion by 2025, according to a new report by Grand View Research, Inc. Introduction of assay methods that enable protein estimation at lower limits of concentration in order to monitor the changes is expected to drive growth in the coming years.

Governments are encouraging the research activities by raising funds in the field of proteomics industry and thus the protein detection and quantification market is anticipated to grow at a significant pace in the coming years. Presence of organizations such as the Human Proteome Organization, National Cancer Institute (NCI) and Genomic Health Inc. promotes funding to support R&D and product development exercises pertaining to the field of proteomics.

View Summary Of This Report Click Here: www.grandviewresearch.com/industry-analysis/protein-detection-quantification-market

Growing need to understand chronic diseases at a molecular level and develop therapeutic solutions is expected to encourage these organizations to fund research and development programs. In addition, Public Health Genomics at the National Cancer Institute (NCI) promotes the integration of personalized medicine and genomics into public health cancer research in an attempt to reduce the burden of cancer across the globe

Although technological advancements continue to take place for simplification protein estimation, high cost of technology and assays are anticipated to restrict the usage of these assays and technologies under certain circumstances. For instance, Mass Spectroscopy (MS) which are often used for functional proteomics is considered expensive and slow by researchers. In targeted MS, custom antibodies are required for each target to perform immunoaffinity enrichment of peptides. This process is observed to be expensive as well as lengthy.

Further key findings from the report suggest:

• Colorimetry dominated with the largest share sue to presence of significant usage of the reagents and solutions for laboratory analysis
• Immunological methods and spectrometric methods are anticipated to grow at similar rates and exhibit fastest Y-o-Y growth
• Advancements in these segments such as FTIR and SMCxPRO technology are attributive for the projected growth rate
• Consumables accounted for the largest share due to wider availability and usage of kits and reagents
• Clinical diagnosis is expected to register fastest progress in the coming years as a result of rising adoption these methods
• Substantial use of technology in target identification and other steps of drug discovery is attributive for the largest share of drug discovery as an application of estimation of these biomolecules
• Academic organizations dominated with respect to use of these protocols and clinical diagnostic labs anticipated to witness fastest progress
• North American region accounted for the largest share as a consequence of large number of proteomics projects implemented herein
• Asia Pacific market is expected to grow at the most lucrative pace due to changing health care infrastructure in this region which drives the demand for these products
• Key players operating include PerkinElmer Inc, GE Healthcare, Inanovate, Thermo Fisher Scientific, Danaher, Merck & Co., Inc., Bio-Rad Laboratories, Inc., Shimadzu Corporation, and RayBiotech, Inc.
• These companies are engaged in collaborations, mergers & acquisitions for the new product launches that rely on the conventional technology but provide novel application in the field of proteomics

To learn more about this report: www.goo.gl/oEfP7M